NCT02631044 2024-06-27
Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)
Juno Therapeutics, a Subsidiary of Celgene
Phase 1 Completed
Juno Therapeutics, a Subsidiary of Celgene
University of Utah
AbbVie